Quest Diagnostics Incorporated
NYSE: DGX · HEALTHCARE · DIAGNOSTICS & RESEARCH
Updated 2026-06-05
Quest Diagnostics Incorporated (DGX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.27B | $6.70B | $7.25B | $7.46B | $7.37B | $7.51B | $7.38B | $7.15B | $7.43B | $7.49B | $7.51B | $7.71B | $7.53B | $7.73B | $9.44B | $10.79B | $9.88B | $9.25B | $9.87B | $11.04B |
| Revenue growth (YoY) | — | +7.0% | +8.1% | +2.8% | -1.2% | +1.9% | -1.7% | -3.2% | +4.0% | +0.8% | +0.3% | +2.6% | -2.3% | +2.6% | +22.1% | +14.3% | -8.4% | -6.4% | +6.7% | +11.8% |
| Cost of revenue | $3.70B | $3.97B | $4.26B | $4.32B | $4.32B | $4.40B | $4.36B | $4.33B | $4.64B | $4.66B | $4.62B | $4.72B | $4.93B | $5.04B | $5.80B | $6.58B | $6.45B | $6.20B | $6.63B | $7.51B |
| Gross profit | $2.57B | $2.74B | $2.99B | $3.13B | $3.05B | $3.12B | $3.02B | $2.82B | $2.80B | $2.84B | $2.90B | $2.99B | $2.60B | $2.69B | $3.63B | $4.21B | $3.43B | $3.05B | $3.24B | $3.52B |
| Gross margin | 41.0% | 40.8% | 41.3% | 42.0% | 41.4% | 41.5% | 40.9% | 39.5% | 37.6% | 37.8% | 38.6% | 38.8% | 34.6% | 34.8% | 38.5% | 39.0% | 34.7% | 33.0% | 32.9% | 31.9% |
| R&D | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| SG&A | $1.43B | $1.61B | $1.74B | $1.75B | $1.71B | $1.81B | $1.75B | $1.70B | $1.73B | $1.68B | $1.68B | $1.75B | $1.42B | $1.46B | $1.55B | $1.73B | $1.82B | $1.80B | $1.77B | $1.92B |
| Operating income | $1.13B | $1.09B | $1.22B | $1.36B | $1.30B | $995.00M | $1.20B | $1.48B | $983.00M | $1.40B | $1.28B | $1.17B | $1.10B | $1.23B | $1.97B | $2.38B | $1.43B | $1.26B | $1.35B | $1.60B |
| Operating margin | 18.0% | 16.3% | 16.9% | 18.2% | 17.6% | 13.2% | 16.3% | 20.6% | 13.2% | 18.7% | 17.0% | 15.1% | 14.6% | 15.9% | 20.9% | 22.1% | 14.4% | 13.6% | 13.6% | 14.5% |
| EBITDA | $1.33B | $1.33B | $1.50B | $1.63B | $1.59B | $1.30B | $1.52B | $1.79B | $1.30B | $1.55B | $1.48B | $1.45B | $1.40B | $1.58B | $2.41B | $3.16B | $1.82B | $1.26B | $1.89B | $2.19B |
| EBITDA margin | 21.1% | 19.8% | 20.7% | 21.9% | 21.5% | 17.3% | 20.6% | 25.1% | 17.5% | 20.8% | 19.7% | 18.8% | 18.6% | 20.5% | 25.5% | 29.3% | 18.4% | 13.6% | 19.2% | 19.9% |
| EBIT | $1.13B | $1.09B | $1.24B | $1.37B | $1.33B | $1.02B | $1.24B | $1.51B | $990.00M | $1.25B | $1.23B | $1.18B | $1.09B | $1.26B | $2.05B | $2.75B | $1.38B | $1.26B | $1.40B | $1.62B |
| Interest expense | $0.00 | $0.00 | $185.48M | $144.10M | $146.10M | $170.60M | $168.00M | $162.00M | $167.00M | $153.00M | $143.00M | $153.00M | $169.00M | $180.00M | $166.00M | $152.00M | $148.00M | $152.00M | $226.00M | $264.00M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $586.42M | $339.94M | $581.50M | $729.10M | $720.90M | $470.60M | $555.70M | $849.00M | $556.00M | $709.00M | $645.00M | $772.00M | $736.00M | $858.00M | $1.43B | $2.00B | $946.00M | $854.00M | $871.00M | $992.00M |
| Net income growth (YoY) | — | -42.0% | +71.1% | +25.4% | -1.1% | -34.7% | +18.1% | +52.8% | -34.5% | +27.5% | -9.0% | +19.7% | -4.7% | +16.6% | +66.8% | +39.4% | -52.6% | -9.7% | +2.0% | +13.9% |
| Profit margin | 9.4% | 5.1% | 8.0% | 9.8% | 9.8% | 6.3% | 7.5% | 11.9% | 7.5% | 9.5% | 8.6% | 10.0% | 9.8% | 11.1% | 15.2% | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
Frequently asked questions
What is Quest Diagnostics Incorporated's revenue?
Quest Diagnostics Incorporated's trailing twelve-month revenue is $11.28B, and consensus projects about $14.02B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is DGX?
In its most recent fiscal year, DGX ran a gross margin of 31.93%, an operating margin of 14.53%, and a net margin of 8.99%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does DGX generate?
DGX produced $1.36B in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is DGX's balance sheet healthy?
DGX holds $420.00M in cash and equivalents against $5.17B in long-term debt, on $7.17B of shareholder equity. That debt is best read against the cash flow the business throws off each year.